# A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

> **NCT06385925** · PHASE1,PHASE2 · RECRUITING · sponsor: **Tyligand Pharmaceuticals (Suzhou) Limited** · enrollment: 440 (estimated)

## Conditions studied

- Malignant Neoplasm

## Interventions

- **DRUG:** TSN1611
- **DRUG:** TSN1611
- **DRUG:** TSN1611
- **DRUG:** TSN1611

## Key facts

- **NCT ID:** NCT06385925
- **Lead sponsor:** Tyligand Pharmaceuticals (Suzhou) Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-29
- **Primary completion:** 2026-10-30
- **Final completion:** 2027-04-30
- **Target enrollment:** 440 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06385925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06385925, "A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06385925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*